Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.otcmarkets.com/stock/VIICQ/quote
Plus it has OTC Pink Sheets:
About OTC Pink Sheets:
Investors should be aware of four cautions. First, most OTC stocks do not meet the minimum requirements for most exchanges and do not file with the SEC. Therefore, credible and reliable fundamental data are not available for analysis. Second, historically Pink Sheets stocks are penny stocks and are often near-insolvent companies. Third, some stocks are illegitimate shell companies set up to scam investors by issuing press releases, and having “analysts” promote the stock and issue more worthless shares. Fourth, Pink Sheets only has one requirement for a company to list - a company needs to have one market maker quoting its stock. The listing companies do not have to provide any financial information at all.
One common scam involving OTC investors is the pump and dump scheme where promoters buy penny stocks, promote and push up the prices for other investors and then dump their stocks while the late investors are stuck with worthless stock that they overpaid to own. These stocks are often promoted in spam emails or on message boards and blogs.
Thanks! I added the SEC information to this WSTI board.
Can't wait for the uplist by strength. All the milestones, partnerships and also LymPro will be in the market.
A Global Opportunity: WindStream Third Quarter Report
Oct 30, 2014
http://www.marketwatch.com/story/a-global-opportunity-windstream-third-quarter-report-2014-10-30
AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is Making Moves
BY JAMES ELLIOT ON - OCTOBER 29, 2014
http://www.microcapdaily.com/amarantus-biosci-incotcmktsambs-is-making-moves/15235/
I did not know that tkstf are using OTC with Pink Sheets. That is really bad to buy shares without SEC. Also partnership with Softbank (OTCPK:SFTBF) that have pink sheets.
About OTC Pink Sheets:
Investors should be aware of four cautions. First, most OTC stocks do not meet the minimum requirements for most exchanges and do not file with the SEC. Therefore, credible and reliable fundamental data are not available for analysis. Second, historically Pink Sheets stocks are penny stocks and are often near-insolvent companies. Third, some stocks are illegitimate shell companies set up to scam investors by issuing press releases, and having “analysts” promote the stock and issue more worthless shares. Fourth, Pink Sheets only has one requirement for a company to list - a company needs to have one market maker quoting its stock. The listing companies do not have to provide any financial information at all.
One common scam involving OTC investors is the pump and dump scheme where promoters buy penny stocks, promote and push up the prices for other investors and then dump their stocks while the late investors are stuck with worthless stock that they overpaid to own. These stocks are often promoted in spam emails or on message boards and blogs.
Alzheimer's Association Alzheimer's Disease Facts and Figures
About PsychoGenics (PGI)
PsychoGenics is a leader in in vivo phenotypic drug discovery. The Company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics' capabilities also include standard behavioral testing, electrophysiology, molecular biology and state-of-the-art microdialysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington’s disease, Autism spectrum disorders, psychosis/schizophrenia, Alzheimer’s disease, Parkinson’s disease, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders.
OTC Pink Sheets - Investors should be aware of four cautions. First, most OTC stocks do not meet the minimum requirements for most exchanges and do not file with the SEC. Therefore, credible and reliable fundamental data are not available for analysis. Second, historically Pink Sheets stocks are penny stocks and are often near-insolvent companies. Third, some stocks are illegitimate shell companies set up to scam investors by issuing press releases, and having “analysts” promote the stock and issue more worthless shares. Fourth, Pink Sheets only has one requirement for a company to list - a company needs to have one market maker quoting its stock. The listing companies do not have to provide any financial information at all.
One common scam involving OTC investors is the pump and dump scheme where promoters buy penny stocks, promote and push up the prices for other investors and then dump their stocks while the late investors are stuck with worthless stock that they overpaid to own. These stocks are often promoted in spam emails or on message boards and blogs.
JN - Why I'm Still Optimistic On LymPro And Amarantus Bio
http://seekingalpha.com/article/2388125-why-im-still-optimistic-on-lympro-and-amarantus-bio
And more articles about AMBS from JN
http://seekingalpha.com/symbol/AMBS
Most likely they are using fake names and etc. Also we do not know what Country they are from. It will not be easy. If you can find they, then you can report them.
OTC Pink - an open marketplace for a broad spectrum of equity securities, with no financial standards or reporting requirements.
OTC Markets require companies to be current in their SEC or other regulatory disclosure to be quoted in the OTCQB marketplace. Companies must also be current in providing disclosure to be quoted in the OTCQX marketplace, though that requirement can be met by providing information in accordance with OTC Link's proprietary Alternative Reporting Standard rather than through filing with the SEC or a banking or insurance regulator.
Companies quoted in the OTC Pink tier are assigned different symbols by OTC Markets, depending on whether they have provided "current" information, "limited" information or "no information." You can find the symbol currently assigned to a stock by OTC Markets and read more about the OTC Market marketplaces at www.otcmarkets.com.
http://www.sec.gov/investor/pubs/microcapstock.htm
zack.com said that the next earnings for AMBS announcement will be on Nov. 13, 2014.
bloomberg.com said the next earnings for AMBS will be on Nov. 14, 2014
I guess sometime in Nov.
Need more news. Hopefully tomorrow.
He started buying AMBS shares this morning.
Interesting Video!
Malaysia Eco-Housing Project to Include Hybrid Solar Wind System
August 04, 2014
WindStream Technologies SolarMill® Hybrid Wind and Solar Energy System to Power 800 Homes in Sungai Ular, Cherating Pahang, Malaysia
http://www.marketwired.com/press-release/malaysia-eco-housing-project-to-include-hybrid-solar-wind-system-otcqb-wsti-1935031.htm
JPS eStore Solar Mill Hybrid solar wind generator product review!
http://rodgermckenzie.wordpress.com/2013/11/11/jps-estore-solar-mill-hybrid-solar-wind-generator-product-review/
10-Q: WINDSTREAM TECHNOLOGIES, INC. Published: May 13, 2014
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
http://www.marketwatch.com/story/10-q-windstream-technologies-inc-2014-05-13
That does not sounds to good.
Best to stay as a long term, you can make big money with AMBS. Good Luck!
Your opinion is totally wrong! Need Proof!
You should not say things that in not true. Give us proof.
Well said!
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”
That's okay, you can think whatever you want. I really believe that AMBS is going a lot higher. Good Luck!
AMARANTUS BIOSCI INC(OTCMKTS:AMBS) Developer of LymPro on Watch Here!
http://www.microcapdaily.com/amarantus-biosci-incotcmktsambs-developer-of-lympro-on-watch-here/14911/
Yes, it would be nice. Hopefully soon!
It is up to you to wait, but I would not want to miss the uplist. Good Luck!
Also partnerships
Gerald E. Commissiong - We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
Plus LymPro will be in the market soon.
I believe they do not need RS. Good Luck!
Blackouts light up home solar power business
By Rohit Vaid - New Delhi, Oct 14
http://www.daijiworld.com/news/news_disp.asp?n_id=270016
Never buy OTC that have Pink Sheets!
Can't wait for MANF to get into the Market!
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
That is a really good news! I have Rong Wen, M.D on my Sticky.
Whatever you believe, that's okay. You never know when pps could pop up. When it do, I hope it will be soon. Good Luck!
No, Gerald is giving us good news and doing is best for the shareholders. I would not like to see Gerald to step down.
The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects. The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.
Amarantus anticipates launching LymPro in the fourth quarter of 2014. Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014, primarily targeting pharmaceutical clinical trials. The company does not require Clinical Laboratory Improvement Amendments (CLIA) certification to launch LymPro in the RUO market.
"Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
Sounds really good! Way to go AMBS!
Remember that Gerald mentioned that they will only consider an up list from a position of strength while the Company is making good progress in the market. They believe the milestones they have outlined above – for the end of 2014 alone – will put them in that position. However, if they do not believe have achieved sufficient shareholder value creation, they will consider delaying the up list until such time as the market recognizes there true value.
Looking good for the end of 2014!